AI takes on heart failure: could it cut hospital stays?
NCT ID NCT07380555
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether an artificial intelligence (AI) system can help doctors manage medications for people with heart failure with reduced ejection fraction (HFrEF). About 1,200 participants from 60 hospitals will be assigned to either AI-guided care or standard care. The goal is to see if AI reduces hospitalizations and heart-related deaths over 12 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- artificial intelligence decision support system
- What this could lead to
- If successful, this could show that AI helps doctors choose better medications for heart failure, potentially reducing hospital stays and saving lives.
- What could go wrong
- This is a large but early-stage study without results yet. The AI recommendations may not improve outcomes over standard care, and the system's accuracy depends on data quality.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH REDUCED EJECTION FRACTION (HF-REF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Zhongshan Hospital
Shanghai, Shanghai Municipality, 200032, China